Immunotherapy for hormone receptor‒positive HER2-negative breast cancer

Fatima Cardoso; Kim M Hirshfield; Kimberly A Kraynyak; Konstantinos Tryfonidis; Aditya Bardia

doi:10.1038/s41523-024-00704-9

Immunotherapy for hormone receptor‒positive HER2-negative breast cancer

NPJ Breast Cancer. 2024 Dec 6;10(1):104. doi: 10.1038/s41523-024-00704-9.

Authors

Fatima Cardoso¹, Kim M Hirshfield², Kimberly A Kraynyak², Konstantinos Tryfonidis², Aditya Bardia³

Affiliations

¹ Breast Unit, Champalimaud Clinical Center/Champalimaud Foundation, Lisbon, Portugal. fatimacardoso@fundacaochampalimaud.pt.
² Merck & Co., Inc., Rahway, NJ, USA.
³ Department of Medicine, Division of Hematology/Oncology, University of California Los Angeles, Jonsson Comprehensive Cancer Center, Los Angeles, CA, USA.

Abstract

Additional therapies are needed to improve outcomes in patients with hormone receptor-positive/human epidermal growth factor receptor 2-negative breast cancer. Research on the potential role of immunotherapy, particularly programmed cell death protein 1/programmed cell death ligand 1 inhibitors, is rapidly expanding in both the early and metastatic settings with some preliminary evidence suggesting benefit when used as part of combination therapy. Several ongoing phase 3 studies should help define their future role in treating these patients.

Publication types

Review